Nov 10, 2025 | Press Releases
New Biologics Patent Application Covers Potential Applicability of TLR5 Agonists to Improve Outcomes for Late-stage Cancer Therapies; Bioelectronic Patent Covers Optimized ncVNS Device Specifications FREMONT, Calif. – Tivic Health® Systems, Inc. (Nasdaq:...
Nov 6, 2025 | Press Releases
FREMONT, Calif. – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30...
Oct 22, 2025 | Press Releases
FREMONT, Calif. – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She...
Sep 22, 2025 | Press Releases
FREMONT, Calif. – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that the company’s CEO will present during the Emerging Growth virtual conference set to take place on September 24 & 25, 2025....
Sep 10, 2025 | Press Releases
FREMONT, Calif. – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it has completed verification of its Entolimod™ cell line, the first step in establishing Current Good Manufacturing Practices...
Aug 20, 2025 | Press Releases
INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regulatory Pathway and Enable Pursuit of Clinical Trial Program in Neutropenia and Lymphocyte Exhaustion FREMONT, Calif. – Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified...